为ENYO Pharma和Eye Tech Care两家企业贯标首批法国科技#健康科技 F 里昂生物孵化器Lyonbiopole-FrenchHealthcareAlliance
在2018年12月18日-继口头答辩后四川升降机 ，由Lyonbiop?le组织的＃healthtech评选委员会将ENYO Pharma 和 Eye Tech Care ENYO两家公司加入2018年法国科技推广项目列表变身武娘 。它们的入选使得来自Auvergne-Rh?ne-Alpes地区的项目获奖数增加到4名。这次成功贯标体现了Lyonbiopole的积极推动作用。Lyonbiopole是“法国科技 French Tech”标志贯标活动在健康技术领域的主要执行方。两家获奖公司同时也是Lyonbiopole董事会成员，将受益于法国科技 French Tech推广活动对其发展的金牌支持。
原文链接（法语）：
Lyonbiop洪瑛琦 ?le 1er opérateur national du Pass French Tech #healthtech labellise ENYO Pharma et Eye Tech Care
https://lyonbiopole.com/actualites/lyonbiopole-1er-operateur-national-pass-french-tech-healthtech-labellise-enyo-pharma-eye-tech-care
About EnyoPharma-感染和代谢疾病的创新化学分子开发
ENYO Pharma is a privately held clinical stage biopharmaceutical company incorporated in January 2014. Founders are a mix of virus-host protein interactions experts from the French Infectiology Research Center in Lyon and pharmaceutical industry executives with an impressive track record in drug development. The company is developing new small molecule therapeutics, mainly first-in-class撒旦僵尸女 , in various therapeutic areas with unmet medical needs.
The company is headquartered in Lyon六道沉沦 , France and has also a subsidiary in Melbourne, Australia. Since its inception, ENYO Pharma’s leadership team has already raised 64.2 million € for its development and is continuously growing.
ENYO Pharma is pioneering a brand new approach and has built a unique drug discovery engine based on biomimetism of the secular strategy how viruses have adapted during evolution to hijack the human cellular functions for their own benefit.
ENYO Pharma owns an exhaustive database of all known virus/human protein-protein interactions from which new cellular targets are discovered. From that叶紫涵 , small active molecules are designed and developed until Phase II clinical trials internally or through partnerships. The company is currently developing treatments against metabolic diseases王品木, infectious diseases and in oncology.
http://www.enyopharma.com/
Eye Tech Care-利用突破性超声技术治疗青光眼
EYE TECH CARE, based in Lyon金嘉名筑 , was founded in 2008 by experts in the field of therapeutic ultrasound. The company develops and markets medical devices for the non invasive treatment of eye diseases.
Glaucoma and ocular hypertension affect some 120 million people around the world王爷的弃妃 , but are diagnosed in only about 30% of cases. It is the second cause of blindness恒星的一生, according to WHO (World Health Organization).
With the support of renowned scientific and financial partners, EYE TECH CARE has developed the EyeOP1, an unique therapeutic device. Its teams have designed the only medical procedure that currently addresses all patients with uncontrolled glaucoma九尾狐外传, irrespective of their prior treatment history.
This non-invasive, extremely precise treatment冯改朵 , offers a very good tolerance profile without significant side effects. It can be performed in less than three minutes in an outpatient care setting.
This technology is unique and the company presently holds a remarkable IP portfolio.
Results from clinical investigations conducted have led to issuance of CE-marking in June 2011 by the LNE/G-MED - Notified body N°0459. The EyeOP1 device is currently marketed in Europe. The LNE also certifies the quality management system developed by EYE TECH CARE.
http://www.eyetechcare.com/en/
About La French Tech
For some years now, the French Tech ecosystem has seen a spectacular growth, driven by a new generation of entrepreneurs, investors曹力伟 , engineers东华上仙 , and other talented people. The number of startups is exploding, fundraisings are exponential, and the number of international market leaders is growing: BlaBlaCar, DBV Technologies覃维妮, Criteo to name a few.
This vibrant ecosystem is called “La French Tech,” a movement for entrepreneurs伟伦体校, by entrepreneurs and backed by the French Tech Initiative瞿鸿燊 ,岑碧青 an innovative public policy created by the French Government in 2013. The French Tech Initiative is boosting this collective dynamic柯凡录音门 , and its actions have taken part in establishing this ecosystem within the French economic landscape. Startups are now considered serious players that create economic value and inspire innovation.
Check out the brochure A Booming Startup Ecosystem (http://www.lafrenchtech.com/sites/default/files/documents/ft-boomingstartup-175x240-corrige.pdf ) to fully discover La French Tech!
https://visa.lafrenchtech.com/